Skip to main content
. 2020 Jul 1;15(8):1090–1102. doi: 10.2215/CJN.01030120

Table 4.

Description of adverse drug reactions according to baseline eGFR

Type of Adverse Drug Reaction All Adverse Drug Reactions, n=751 Adverse Drug Reactions in Patients with eGFR≥30, n=331 Adverse Drug Reactions in Patients with eGFR<30, n=420
Renal and urinary disorders 150 (20%) 62 (19%) 88 (21%)
 AKI 102 41 61
 Increased serum creatinine 40 20 20
 Other type of renal and urinary disorders 8 1 7
Gastrointestinal disorders 119 (16%) 61 (18%) 58 (14%)
 Diarrhea 57 35 22
 Gastrointestinal conditions 24 8 16
 Other type of gastrointestinal disorders 38 18 20
Musculoskeletal and connective tissue disorders 68 (9%) 34 (10%) 34 (8%)
 Contractures 35 21 14
 Muscle pain 22 10 12
 Other type of musculoskeletal and connective tissue disorders 11 3 8
Hemorrhages and bleeding 67 (9%) 18 (5%) 49 (12%)
 Hemorrhages 34 8 26
 Hematoma 19 7 12
 Other type of hemorrhages and bleeding 14 3 11
General disorders and administration site conditions 58 (8%) 26 (8%) 32 (8%)
 Peripheral edema 30 11 19
 Drug intolerance 8 3 5
 Other type of general disorders and administration site conditions 20 12 8
Other type of adverse drug reactions 289 (38%) 130 (39%) 159 (38%)

eGFR is expressed in milliliters per minute per 1.73 m2. Results are expressed as n (%). The denominator used in column 2 is the total number of adverse drug reactions, and the denominators used in columns 3 and 4 are those of the adverse drug reactions in patients with eGFR<30 versus ≥30, respectively. P=0.03 tests the difference in the distribution of adverse drug reaction type according to patient baseline eGFR.